Core Viewpoint - SaiLu Medical has completed A+ round financing led by Fosun Pharma, with funds aimed at upgrading domestic sequencing platforms and expanding market presence, driving innovation in life science tools [1][2]. Group 1: Financing and Investment - The A+ round financing was led by Fosun Pharma, with participation from Weichi Investment and existing shareholder Shenzhen Capital Group [2]. - The funds will be primarily used for the registration and declaration of domestic sequencing platforms, capacity expansion, and global market development [2][3]. Group 2: Company Development and Achievements - Since its establishment in 2020, SaiLu Medical has maintained rapid development, achieving significant milestones such as obtaining the NMPA Class III medical device registration for its Salus Pro sequencer in January 2025 [2]. - The company has built a comprehensive R&D system covering optics, fluidics, chips, and reagents, and has accumulated over 100 authorized patents [3]. Group 3: Strategic Collaboration - The financing marks a new phase of strategic cooperation between Fosun Pharma and SaiLu Medical, focusing on product development, resource integration, and global market expansion [6]. - Both companies will emphasize "innovation-driven" strategies to accelerate the development of innovative technologies and products that meet clinical needs [6].

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has initiated a Phase I/III clinical trial for HLX13, a biosimilar of ipilimumab, targeting unresectable advanced hepatocellular carcinoma (HCC) patients in China [2]. HLX13 Information and Research Status - HLX13 is a biosimilar of ipilimumab developed by the group, intended for treating multiple cancers including melanoma, renal cell carcinoma, colorectal cancer, HCC, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma [3]. - As of April 2025, the group has invested approximately RMB 104 million (about $15 million) in the development of HLX13 [3]. - According to IQVIA MIDASTM data, global sales of ipilimumab formulations are projected to reach approximately $2.873 billion in 2024 [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 陳玉卿 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品臨床試驗進展的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 中國，上海 2025 年5 月1 6 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 证券代码：60019 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-089 截至 2025 年 4 月，本集团现阶段针对 HLX13 累计研发投入约为人民币 1.04 亿 元（未经审计）。 根据 IQVIA MIDAS TM最新数据 1，2024 年，伊匹木单抗制剂于全球范围内的销售 额约为 28.73 亿美元。 上海复星医药（集团）股份有限公司 关于控股子公司药品临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的伊匹木单抗生物 类似药 HLX13（重组抗 CTLA-4 全人单克隆抗体注射液，以下简称"HLX13"）一线 治疗不可切除的晚期肝细胞癌（HCC）患者于中国境内启动 I/III 期临床试验。 二、HLX13 的基本信息及研究情况 HLX13 为本集团（即本公司及控股子公司/单位，下同）自主研发的伊匹木单抗 生物类似药，拟用于治疗黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to continue its growth driven by sustained high investment in R&D and ongoing internationalization and innovation efforts [1][5] - The company reported a rapid profit growth and improved cash flow, with a 2024 revenue of 41.067 billion yuan, a slight decrease of 0.80% year-over-year [1] - The core innovative products, including the PD-1 monoclonal antibody and CAR-T cell therapy, have shown steady revenue growth [1][2] Summary by Sections Financial Performance - In 2024, the company achieved a net profit of 2.770 billion yuan, an increase of 16.08% year-over-year, with a non-GAAP net profit of 2.314 billion yuan, up 15.10% [2] - The gross margin improved, and the selling expense ratio increased by 2.45 percentage points year-over-year, while management expenses decreased by 355 million yuan [2] Business Segmentation - The pharmaceutical segment generated 28.924 billion yuan in revenue, with a segment profit of 3.250 billion yuan, reflecting a year-over-year growth of 65.73% [3] - The medical devices and diagnostics segment reported a revenue of 4.323 billion yuan, a decrease of 1.53% due to declining COVID-related product sales [3] - The healthcare services segment achieved a revenue of 7.647 billion yuan, an increase of 14.61%, although it still reported a loss of 315 million yuan [4] Future Outlook - The company plans to maintain high R&D investment, with a total of 5.554 billion yuan allocated in 2024, representing 16.98% of the pharmaceutical business revenue [5] - The company is advancing its internationalization strategy, with several products receiving approvals in the US and Europe [6][11] - The earnings per share (EPS) forecast for 2025-2027 is projected at 1.22, 1.37, and 1.57 yuan, respectively, with a price-to-earnings (P/E) ratio of 20 times based on the closing price on May 13, 2025 [12]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to continue its growth driven by ongoing innovation and internationalization efforts [1][5] - The company reported a rapid profit growth and improved cash flow for 2024, with operating revenue reaching 41.067 billion yuan, a year-over-year decrease of 0.80% [1] - The company achieved a net profit of 2.770 billion yuan in 2024, an increase of 16.08% year-over-year, with a non-GAAP net profit of 2.314 billion yuan, up 15.10% [2] Summary by Sections Performance Overview - The company’s revenue for 2024 was 41.067 billion yuan, with innovative products contributing to steady growth [1] - Operating cash flow improved to 4.477 billion yuan, a year-over-year increase of 31.13% [1] Business Segmentation - The pharmaceutical segment generated revenue of 28.924 billion yuan in 2024, with a segment profit of 3.250 billion yuan, reflecting a year-over-year growth of 65.73% [3] - The medical devices and diagnostics segment reported revenue of 4.323 billion yuan, a decrease of 1.53% year-over-year, primarily due to declining COVID-related product sales [3] - The healthcare services segment achieved revenue of 7.647 billion yuan, a year-over-year increase of 14.61%, although it still reported a segment loss of 315 million yuan [4] Future Outlook - The company plans to maintain high R&D investment, with total R&D expenditure reaching 5.554 billion yuan in 2024, representing 16.98% of pharmaceutical revenue [5] - The company is advancing its internationalization strategy, with several products receiving approvals in international markets, including the US and Europe [6] - Earnings per share (EPS) forecasts for 2025-2027 are projected at 1.22, 1.37, and 1.57 yuan, respectively [12]

Group 1 - Shenzhen Sailu Medical Technology Co., Ltd. has completed A+ round financing led by Fosun Pharma, with participation from Weichi Investment and existing shareholder Shenzhen Capital Group [1] - The funds will be used for the registration of a national sequencing platform, capacity expansion, and global market development, reinforcing its position in the life sciences tools sector [1] - Founded in 2020, Sailu Medical is a national high-tech enterprise focusing on developing proprietary upstream sequencing platforms and has built a leading super-resolution spatial omics platform [1] Group 2 - The Salus Pro sequencer developed by Sailu Medical received NMPA Class III medical device registration in January 2025, becoming the first domestic device to cover all application scenarios based on reversible terminator sequencing [2] - The company has established a comprehensive R&D system covering optics, fluidics, chips, and reagents, aiming to become a global leader in life science tools [2] - The financing marks a new phase of strategic cooperation between Fosun Pharma and Sailu Medical, focusing on product development, supply chain integration, and global market expansion [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 為控股子公司提供擔保的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 证券代码：600196 股票简称：复星医药 编号：临 2025-088 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 陳玉卿 中國，上海 2025 年5 月1 ...

上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《第九 屆董事會第七十九次會議（臨時會議）決議公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年5 月1 3 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、徐曉亮先生、潘東輝先生及吳以芳先生；以及本公司之獨立非執行董事為李玲女士、湯 谷良先生、王全弟先生及余梓山先生。 * 僅供識別 上海复星医 ...

Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has made adjustments to the general authorization for issuing corporate bonds to enhance the efficiency of the bond issuance process [1][2]. Group 1: Meeting Details - The ninth board of directors held its seventy-ninth meeting on May 12, 2025, with all directors attending via communication [1]. - The meeting complied with the Company Law of the People's Republic of China and relevant regulations [1]. Group 2: Authorization Adjustment - The board approved a resolution to adjust the authorized representatives for the issuance of corporate bonds, allowing the chairman, co-chairman, or vice-chairman to act as authorized representatives [1]. - The previous authorization allowed only the chairman or vice-chairman, which has now been expanded to include the co-chairman [1]. Group 3: Voting Results - The voting results for the resolution showed 12 votes in favor, with no votes against or abstentions [2]. - The revised authorization still requires approval from the shareholders' meeting [2].